Latest News

Medtrade partners with KEBOMED Europe AG to help control postpartum haemorrhage

From Battlefield to Bedside- CELOX success story- BBC World Series Interview with Medtrade CEO Russ Mably

Medtrade partners with Laubscher & Co to address postpartum haemorrhage across Switzerland

Medtrade Products Ltd is delighted to announce that it has entered into an exclusive agreement with Laubscher & Co AG to distribute the revolutionary CELOX™ PPH Uterine Haemostatic Tamponade in Switzerland.
Read more

Medtrade partners with Dahlhausen^® Medizintechnik to reach maternity units across Germany and Austria

Medtrade Products Ltd is delighted to announce that it has entered into an exclusive agreement with Dahlhausen^® Medizintechnik to …
Read more

Rapid and Effective control of Uterine Postpartum Haemorrhage (PPH)

Extensive clinical experience demonstrating:

100% haemostasis for grade 1 & 2 (up to 2500mls) bleeding in all deliveries¹
78% reduction in hysterectomies vs current standard of care^{2, 3, 4}
Safe and Easy to use with minimal product training requirements^{1, 2, 3, 4}

Celox PPH Product IFU

Celox PPH Brochure

“All attempts should be made to reduce PPH using cost effective, resource appropriate interventions”

The international Federation of Gynaecology and Obstetrics

“Most common cause of maternal death worldwide”

World Health Organisation

20%Failure rates of existing devices¹ 14mWomen impacted Globally by PPH⁵ 20%Maternal deaths due to PPH worldwide⁶ 80kAnnual Deaths caused by PPH⁷Postpartum Haemorrhage is the leading cause of maternal mortality worldwide representing over 80,000 deaths worldwide. 7.2% to 25.7%Rate of PPH (Blood loss >500ml) across all global markets⁸The rate of PPH varies significantly across both low income and developed nations with an incidence ranging from 7.2% to 25.7% variable by geographic region (defined as >500ml blood loss in vaginal births) representing over 14 million pregnant woman who suffer from this condition.

With such significant global challenges associated with PPH we are passionate about supporting research and development across reproductive health, with a versatile, easy to use, cost effective, clinically successful device.

Our Mission

Our Mission is to make a significant global impact in helping to reduce maternal death worldwide. We aim to support at every delivery across the world through access to a safe and clinically effective technology which is fast acting in all conditions providing versatility and ease of use.

Globalisation of technology enabled through Easy to Use design

Compact and small package with 5 year shelf life
Ready to use in seconds
Minimal product training requirements

Our CELOX™ Technology

Fast acting:

Creates a robust gel plug sealing the bleed site⁹
Works independent of classic clotting pathway⁹

Safe and clinical effective supported by a range of peer reviewed published clinical papers^{2, 3, 4}

With over 17 years of leading the way in global management of haemostasis using CELOX™ technology across trauma, emergency services and military applications, we are passionate about extending the application of this innovative solution to create a unique approach to help solve the global challenge posed by PPH.

Our Innovation

CELOX PPH provides Rapid and Effective Control of Uterine Postpartum bleeding

Fast Acting - Unique mode of action reducing the need for further intervention
Safe & Clinically Effective - 10 years of clinical efficacy vs standard of care
Versatile & Easy to Use - Allowing globalisation of the technology in Developed and Developing Nations

“At every delivery across the world”

Our Evidence

10 years clinical efficacy (within PPH applications) vs standard of care demonstrating a Safe and Clinically effective technology

CELOX PPH clinical data supports the following claims:

“CELOX PPH is highly effective in the control and treatment of uterine PPH” “CELOX PPH achieved a success rate of 100% haemostasis for grade 1 & 2 bleeding (up to 2500mls)”¹ “CELOX PPH achieved a success rate of 95.6% haemostasis for grade 1 to 3 bleeding (vaginal deliveries)”¹ “The use of CELOX PPH results in a reduction in hysterectomy rates of up to 78%”^{2, 3, 4} “CELOX PPH achieves haemostasis and avoids further surgical therapy”^{2, 3, 4} “Can be used with patients on anticoagulant therapy or trauma induced coagulopathy”¹